Dupilumab for treatment of eosinophilic fasciitis

Xia, RuiYuan; Liu, Jian; Su, Ting; Xia, Jun; Yin, Zhiqiang

doi:10.1111/ced.15379

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two cases of highly steroid- and immunosuppressant-refractory Well’s syndrome reported complete resolutions [ 239 , 240 ], as did two cases of the related erythema annulare eosinophilicum [ 241 , 242 ]. One case of eosinophilic fasciitis reported resolution of skin induration clinically and in MRI-studies under dupilumab treatment [ 243 ]. Further, one case of angiolymphoid hyperplasia with eosinophilia refractory to IL-5 inhibitors treated with dupilumab reported sustained resolution of pruritic skin lesions even after discontinuation of the therapy [ 244 ].…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract